Clinical Trial Details


Research Study Summary

A long-term 4+ year, double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events


Patients with type 2 diabetes have increased risk of developing cardiovascular complications. Improved control of hyperglycemia or blood pressure reduces the risk of diabetic complications Administration of bexagliflozin, a potent SGLT2 inhibitor, has been shown to be well tolerated and to decrease HbA1c in subjects with type 2 diabetes. Study THR-1442-C-476 is designed to demonstrate that bexagliflozin also improves glucose control in patients at higher risk of cardiovascular events. There may be additional benefits of bexagliflozin of weight loss and reduction of blood pressure.

To Learn more

CW ID: 218159
Date Last Changed: September 1, 2016

Clinical Trial Snapshot

Both Male and Female
40 and up
Overall Status
Lead Sponsor
4 Years
Facility Type


Eligibility criteria:

  • Age ≥ 40 years old
  • Subjects with a diagnosis of diabetes, type 2 and HbA1c values of 7.5 – 11%
  • Stable diabetes treatment regimen for the past 3 months.
  • Subjects who present with at least one of the following cardiovascular histories:
    • Myocardial infarction (heart attack)
    • Stroke
    • Prior coronary artery bypass grafting or coronary stent
    • Congestive heart failure
    • Multiple cardiovascular risk factors including Age ≥ 55 years, diabetes duration of = 10 years, uncontrolled hypertension, current smoking, chronic kidney disease, or low HDL cholesterol


Jeffrey D. Wayne, MD, Principal Investigator
Clinical Trials Research
160 Gateway Drive, Suite 100
Lincoln, CA 95648
Phone: 916-434-8230
Fax: 916-434-8237

View Map

Research Center Information:

Clinical Trials Research

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.